| Literature DB >> 31861460 |
Han-Wei Yeh1, Liang-Tsai Yeh2,3, Ying-Hsiang Chou2,4,5, Shun-Fa Yang2,6, Sai-Wai Ho7,8, Ying-Tung Yeh9,10, Ying-Ting Yeh9,10, Yu-Hsun Wang6, Chi-Ho Chan6,11, Chao-Bin Yeh7,8.
Abstract
The purpose of this study was to analyze the relationship between elevated cardiovascular disease (CVD) risk and type of anesthesia by using the National Health Insurance Research Database (NHIRD) of Taiwan in a one-year follow-up period. We assessed whether general anesthesia (GA) or neuraxial anesthesia (NA) increased CVD occurrence in lower-limb fracture patients. Approximately 1 million patients were randomly sampled from the NHIRD registry. We identified and enrolled 3437 lower-limb fracture patients who had received anesthesia during operations conducted in the period from 2010 to 2012. Next, patients were divided into two groups, namely GA (n = 1504) and NA (n = 1933), based on the anesthetic technique received during surgery. Our results revealed that those receiving GA did not differ in their risk of CVD relative to those receiving NA, adjusted HR = 1.24 (95% CI: 0.80-1.92). Patients who received GA for more than 2 h also did not differ in their risk of CVD relative to those receiving NA for less than 2 h, adjusted HR = 1.43 (95% CI: 0.81-2.50). Moreover, in the GA group (i.e., patients aged ≥65 years and women), no significant difference for the risk of CVD events was observed. In conclusion, in our study, the difference in the risk of CVD between lower-limb fracture patients receiving NA and GA was not statistically significant. The incidence rate of CVD seemed to be more correlated with patients' underlying characteristics such as old age, comorbidities, or admission to the intensive care unit. Due to the limited sample size in this study, a database which reviews a whole national population will be required to verify our results in the future.Entities:
Keywords: cardiovascular diseases; general anesthesia; neuraxial anesthesia
Mesh:
Year: 2019 PMID: 31861460 PMCID: PMC6982192 DOI: 10.3390/ijerph17010033
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Flow chart for patient selection.
Demographic characteristics of general anesthesia (GA) and neuraxial anesthesia (NA) groups.
| Variables | General Anesthesia | Neuraxial Anesthesia | |||
|---|---|---|---|---|---|
| N | % | N | % | ||
| Age | <0.001 | ||||
| <65 | 1080 | 71.8 | 1176 | 60.8 | |
| ≥65 | 424 | 28.2 | 757 | 39.2 | |
| Mean ± SD | 50.7 ± 20.8 | 57.6 ± 20.8 | <0.001 | ||
| Gender | 0.406 | ||||
| Female | 720 | 47.9 | 953 | 49.3 | |
| Male | 784 | 52.1 | 980 | 50.7 | |
| Hypertension | 384 | 25.5 | 565 | 29.2 | 0.016 |
| Hyperlipidemia | 107 | 7.1 | 200 | 10.3 | 0.001 |
| Diabetes | 204 | 13.6 | 321 | 16.6 | 0.014 |
| Renal disease | 39 | 2.6 | 56 | 2.9 | 0.590 |
| Liver disease | 80 | 5.3 | 71 | 3.7 | 0.019 |
| Chronic pulmonary disease | 88 | 5.9 | 153 | 7.9 | 0.019 |
| Intensive care unit (ICU) admission | 127 | 8.4 | 44 | 2.3 | <0.001 |
| Anticoagulants | 69 | 4.6 | 107 | 5.5 | 0.211 |
| Anesthesia time | <0.001 | ||||
| <2 h | 742 | 49.3 | 1377 | 71.2 | |
| ≥2 h | 762 | 50.7 | 556 | 28.8 | |
| Hospital level | <0.001 | ||||
| Medical centers | 553 | 36.8 | 480 | 24.8 | |
| Regional hospitals | 725 | 48.2 | 826 | 42.7 | |
| District hospitals | 180 | 12.0 | 599 | 31.0 | |
| Clinics | 46 | 3.1 | 28 | 1.4 | |
Figure 2Kaplan–Meier curves with a cumulative probability of cardiovascular disease (CVD) following GA and NA in lower-limb fracture patients.
Cox proportional hazard model of risk of CVD events among GA and NA groups.
| Variables | No. of CVD Events | Observed | Incidence Density | Crude HR | 95% CI | Adjusted HR † | 95% CI | ||
|---|---|---|---|---|---|---|---|---|---|
| Group | |||||||||
| Neuraxial anesthesia | 48 | 1861 | 25.8 | 1 | 1 | ||||
| General anesthesia | 38 | 1447 | 26.3 | 1.02 | 0.67–1.56 | 0.933 | 1.24 | 0.80–1.92 | 0.334 |
| Age | |||||||||
| <65 | 18 | 2221 | 8.1 | 1 | 1 | ||||
| ≥65 | 68 | 1087 | 62.6 | 7.67 | 4.56–12.90 | <0.001 | 5.77 | 3.21–10.38 | <0.001 |
| Gender | |||||||||
| Female | 43 | 1616 | 26.6 | 1 | 1 | ||||
| Male | 43 | 1692 | 25.4 | 0.95 | 0.63–1.46 | 0.829 | 1.89 | 1.21–2.95 | 0.005 |
| Hypertension | 52 | 886 | 58.7 | 4.16 | 2.70–6.42 | <0.001 | 1.63 | 0.98–2.70 | 0.059 |
| Hyperlipidemia | 14 | 293 | 47.8 | 2.00 | 1.13–3.54 | 0.018 | 0.91 | 0.49–1.66 | 0.749 |
| Diabetes | 35 | 485 | 72.2 | 3.97 | 2.58–6.11 | <0.001 | 2.09 | 1.29–3.37 | 0.003 |
| Renal disease | 8 | 78 | 102.7 | 4.18 | 2.02–8.66 | <0.001 | 1.48 | 0.70–3.12 | 0.305 |
| Liver disease | 3 | 142 | 21.1 | 0.80 | 0.25–2.54 | 0.707 | 0.58 | 0.18–1.84 | 0.354 |
| Chronic pulmonary disease | 11 | 221 | 49.8 | 2.04 | 1.08–3.84 | 0.027 | 1.21 | 0.64–2.30 | 0.561 |
| ICU admission | 11 | 142 | 77.3 | 3.22 | 1.71–6.06 | <0.001 | 2.59 | 1.35–4.96 | 0.004 |
| Anticoagulants | 14 | 159 | 87.8 | 3.81 | 2.15–6.75 | <0.001 | 1.80 | 0.97–3.31 | 0.061 |
CVD: cardiovascular disease. † Adjusted for age, gender, hypertension, hyperlipidemia, diabetes, renal disease, liver disease, chronic pulmonary disease, ICU admission, and anticoagulant use.
Subgroup analysis of the Cox proportional hazard model at anesthesia time.
| Variables | No. of CVD Events | Observed | Incidence Density | Crude | 95% CI | Adjusted HR † | 95% CI | ||
|---|---|---|---|---|---|---|---|---|---|
| Group | |||||||||
| NA < 2 h | 32 | 1326 | 24.1 | 1 | 1 | ||||
| NA ≥ 2 h | 16 | 535 | 29.9 | 1.24 | 0.68–2.26 | 0.482 | 1.00 | 0.55–1.83 | 0.999 |
| GA < 2 h | 15 | 720 | 20.8 | 0.86 | 0.47–1.60 | 0.641 | 1.05 | 0.57–1.95 | 0.866 |
| GA ≥ 2 h | 23 | 727 | 31.7 | 1.31 | 0.77–2.24 | 0.322 | 1.43 | 0.81–2.50 | 0.217 |
CVD: cardiovascular disease. † NA (neuraxial anesthesia) and GA (general anesthesia). Adjusted for age, gender, hypertension, hyperlipidemia, diabetes, renal disease, liver disease, chronic pulmonary disease, ICU admission, and anticoagulant use.
Subgroup analysis of Cox proportional hazard model using age and sex.
| General Anesthesia | Neuraxial Anesthesia | HR | 95% CI | ||||
|---|---|---|---|---|---|---|---|
| N | No. of CVD Events | N | No. of CVD Event | ||||
| Age † | |||||||
| <65 | 1080 | 7 | 1176 | 11 | 0.60 | 0.21–1.66 | 0.323 |
| ≥65 | 424 | 31 | 757 | 37 | 1.49 | 0.92–2.43 | 0.107 |
| sex ‡ | |||||||
| Female | 720 | 22 | 953 | 21 | 1.68 | 0.92–3.07 | 0.093 |
| Male | 784 | 16 | 980 | 27 | 0.84 | 0.43–1.66 | 0.619 |
CVD: cardiovascular disease. † Adjusted for sex, hypertension, hyperlipidemia, diabetes, renal disease, liver disease, chronic pulmonary disease, ICU admission, and anticoagulant use. ‡ Adjusted for age, hypertension, hyperlipidemia, diabetes, renal disease, liver disease, chronic pulmonary disease, ICU admission, and anticoagulant use.
Sensitivity analysis of risk of CVD events in different follow-up periods.
| N | No. of CVD Event | Adjusted HR † | 95% CI | ||
|---|---|---|---|---|---|
| Follow-up period ≤6 months | |||||
| Group | |||||
| Neuraxial anesthesia | 1933 | 28 | 1 | ||
| General anesthesia | 1504 | 19 | 1.05 | 0.58–1.91 | 0.875 |
| Follow-up period 7–12 months | |||||
| Group | |||||
| Neuraxial anesthesia | 1859 | 20 | 1 | ||
| General anesthesia | 1444 | 19 | 1.52 | 0.79–2.91 | 0.206 |
CVD: cardiovascular disease. † Adjusted for age, sex, hypertension, hyperlipidemia, diabetes, renal disease, liver disease, chronic pulmonary disease, ICU admission, and anticoagulant use.
Track time of CVD following general anesthesia and neuraxial anesthesia.
| Neuraxial Anesthesia | General Anesthesia | |
|---|---|---|
| Follow-up duration (month, mean ± SD) | 11.6 ± 2 | 11.5 ± 2.0 |
| Time to CVD (month, mean ± SD), N = 86 | 4.8 ± 3.6 | 6.0 ± 3.8 |
CVD: cardiovascular diseases.